Health Economics›Esophageal cancer›Metastatic or locally advanced disease first-line

Metastatic or locally advanced disease first-line

Esophageal cancer · 16 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 5 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Cisplatin and Fluorouracil (CF) and Pembrolizumab Variant #01	—	R 82 937	21d	—	12.4 mo	—	—	2
mFOLFOX6 and Cetuximab Variant #02	—	R 76 618	14d	~8.2 mo	~30.9 mo	~18	~R 1 379 118 PFS proxy · indirect	4
LdCF Variant #01	—	R 7 270	14d	—	12.1 mo	—	—	1
Carboplatin and Paclitaxel (CP) Variant #38	—	R 5 031	21d	~7.4 mo	~27.5 mo	~11	~R 55 338 PFS proxy · indirect	3
ECF Variant #04	—	R 3 931	21d	—	9.4 mo	—	—	—
MCF Variant #01	—	R 3 841	42d	—	8.5 mo	—	—	1
EOX Variant #01	—	R 3 411	21d	—	11.3 mo	—	—	1
FULV and Gemcitabine Variant #02	—	R 3 219	21d	—	—	—	—	—
EOF Variant #01	—	R 3 063	21d	—	~48.0 mo	—	—	1
Docetaxel and Irinotecan Variant #01	—	R 2 573	21d	—	—	—	—	—
ECX Variant #01	—	R 2 313	21d	~4.2 mo	~30.6 mo	~7	~R 16 189 PFS proxy · indirect	6
Paclitaxel monotherapy Variant #46	—	R 2 220	28d	—	9.2 mo	—	—	1
Cisplatin and Fluorouracil (CF) Variant #29	—	R 1 900	21d	—	9.8 mo	—	—	2
Cisplatin and Irinotecan (IC) N/A - secondary systemic drug	—	R 743	42d	~3.8 mo	~13.9 mo	~3	~R 2 230 PFS proxy · indirect	2
Cisplatin and Paclitaxel (TP) Variant #01	—	R 716	10d	~5.6 mo	~11.1 mo	~18	~R 12 892 PFS proxy · indirect	8
Best supportive care Partial	—	—	—	—	4.2 mo	—	—	1

16 of 16 regimens shown